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Category formation, grouping and read across methods are broadly applicable in toxicological assess-
ments and may be used to ﬁll data gaps for chemical safety assessment and regulatory decisions. In order
to facilitate a transparent and systematic approach to aid regulatory acceptance, a strategy to evaluate
chemical category membership, to support the use of read-across predictions that may be used to ﬁll data
gaps for regulatory decisions is proposed. There are two major aspects of any read-across exercise,
namely assessing similarity and uncertainty. While there can be an over-arching rationale for grouping
organic substances based on molecular structure and chemical properties, these similarities alone are
generally not sufﬁcient to justify a read-across prediction. Further scientiﬁc justiﬁcation is normally
required to justify the chemical grouping, typically including considerations of bioavailability, metabo-
lism and biological/mechanistic plausibility. Sources of uncertainty include a variety of elements which
are typically divided into two main issues: the uncertainty associated ﬁrstly with the similarity justiﬁca-
tion and secondly the completeness of the read-across argument. This article focuses on chronic toxicity,
whilst acknowledging the approaches are applicable to all endpoints. Templates, developed from work to
prepare for the application of new toxicological data to read-across assessment, are presented. These
templates act as proposals to assist in assessing similarity in the context of chemistry, toxicokinetics
and toxicodynamics as well as to guide the systematic characterisation of uncertainty both in the context
of the similarity rationale, the read across data and overall approach and conclusion. Lastly, a workﬂow
for reporting a read-across prediction is suggested.
 2015 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction and problem formulation
Legislative requirements for registration and safety assessment
of chemicals have demonstrated the need for a new way of think-
ing to obtain toxicological information without resorting to animal
testing. The grouping of substances allowing read-across of toxicity
is a valuable method to obtain such information and potentially
has a number of regulatory applications. The underlying philoso-
phy of read-across is that substances which are similar in chemical
structure will have similar properties and thereby, have similar
toxicokinetic and toxicodynamic properties. Therefore,
experimentally-derived toxicological properties from one
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across to ﬁll the data gap for a second substance, the target chem-
ical, which has a similar chemical structure and for which a toxi-
cology study may be lacking.
Despite the fact that read-across has been used for several
years, a number of challenges remain. For instance, when applying
read-across to make a prediction of toxicity, a number of questions
arise, for which answers may be difﬁcult to arrive at or to docu-
ment; including:
(1) Can a robust group of chemicals (often referred to as a chem-
ical category) be formed to include the target chemical?
(2) Is the category formed relevant for the toxicology of the end-
point under assessment?
(3) Are there appropriate toxicology studies of high enough
quality for the source chemical(s) to allow a meaningful
read-across?
(4) What is the uncertainty and is it acceptable to use the read
across prediction to ﬁll the data gap for a speciﬁc regulatory
purpose?
To begin to address these questions a ﬂexible strategy for devel-
oping and reporting a read-across prediction has been created. The
strategy focuses on the two main elements of any read-across esti-
mation, namely assessing (1) the similarity between target(s) and
source substance(s) and (2) the uncertainties in the read-across
process and ultimate prediction. While the standards for accepting
a read-across prediction can vary between regulatory agencies, a
good basis is the standard required for ﬁlling a REACH registration
information requirement (EC, 2006). Conceptually, this means, for
example, that in the context of a safety assessment for a complete
set of results it should be possible to read-across the ﬁndings of a
28-/90-day repeated-dose oral rat toxicity study on the source sub-
stance(s) to the target substance(s). As such, the aim of the
read-across is to provide a prediction(s) that is (more or less)
equivalent to the omitted standard animal study and hence be
acceptable for regulatory purposes.
The intent of this document is to establish a strategy which may
be used to conduct and document read-across predictions for data
gap ﬁlling. As such, it provides guiding principles for developing
read-across predictions for discrete organic compounds. Where
possible, emphasis has been placed on undertaking and describing
the read-across prediction in the best manner to facilitate regula-
tory acceptance. This document represents, in part, discussions in
and progress made in the European Commission and Cosmetics
Europe funded SEURAT-1 Cluster (www.seurat-1.eu). As such, the
primary focus of this document is directed towards read-across
predictions for chronic toxicity, or improving the possibility to
read-across from repeat dose toxicity tests. However, in order to
achieve this aim, the document draws upon current expertise
and knowledge from other toxicological endpoints and the infor-
mation, templates and work plans contained herein are generally
applicable to all read-across scenarios and endpoints.
In order to facilitate regulatory acceptance, a read-across pre-
diction needs to be justiﬁed in all aspects. Brieﬂy, the justiﬁcation
of a read-across prediction needs to be robust, reliable and easily
explicable. Key principles of similarity need to be clearly docu-
mented and, where possible, supported by scientiﬁc literature
and data. Sources of uncertainty need to be identiﬁed and accom-
modated; these can typically be divided into two main types: (1)
the uncertainty associated with the justiﬁcation of similarity
between the source and target structures, and (2) the uncertainty
associated with the application of the particular read-across
exercise.
Whilst no consensus has been reached by stakeholders and
users, there is growing agreement that when read-across is appliedto make predictions to fulﬁl information requirements, this must
be done on an endpoint-by-endpoint basis, i.e. for the particular
toxicology study to be predicted. This approach to apply to end-
points individually is due, even when there is an over-arching cat-
egory hypothesis, to different applicability domains, different
source chemicals and/or different Weights-of-Evidence (WoE)
which may apply to making predictions for different endpoints.
Obviously, there will be occasions where one or more endpoints
will be closely related and knowledge may be transferable, thus
allowing read-across arguments to build, partially, on each other.
It is generally agreed that the acceptability of a read-across pre-
diction relies on the explanation of the similarity which forms the
basis of the read-across, as well as the description of the type and
degree of uncertainty associated with the particular read-across.
Therefore, it is important to address these two elements in a trans-
parent and consistent manner. The use of templates or work plans
facilitates the elucidation of the transparency and consistency in
read-across. Existing templates or reporting formats for
read-across vary in detail, however, it is generally agreed that they
aim to:
(1) Describe the rationale for the similarity between the source
and target chemical in a transparent manner.
(2) Document the logic and data leading to the read-across pre-
diction so that, if required, it can subsequently be recreated.
(3) Describe the uncertainties in the prediction; speciﬁcally sep-
arating the uncertainties in data and deﬁnition of similarity
from procedural uncertainty.
(4) Clarify the roles of any endpoint speciﬁc and/or endpoint
non-speciﬁc factors affecting the assessment.
2. Background
Read-across is an alternative method for ﬁlling data gaps based
on an analogue or chemical category approach (van Leeuwen et al.,
2009). It is the process of assessing a toxic endpoint of an untested
substance (i.e., target chemical) based on the results for the same
endpoint for a tested substance (i.e., source chemical) considered
to be ‘‘similar’’ in the context of structure, properties and/or activ-
ities (Dimitrov and Mekenyan, 2010). It is recognised that forming
a chemical category and data gap ﬁlling by interpolation within the
category, especially for hazard assessments, is not a new concept
(OECD, 2014a). However, greater emphasis has now been placed
on the resultant read-across prediction due to legislative pressure,
especially within Europe, and especially for classiﬁcation and
labelling, and risk assessment. Currently, there is growing interest
in several national Governmental regulatory agencies to establish
best practices for conducting and evaluating read-across within
the context of, and to enable, regulatory decisions. Published exer-
cises and case studies using the OECD QSAR Toolbox (cf. Enoch
et al., 2013) have demonstrated that category-based read-across
can be used to establish that a substance is associated with poten-
tially hazardous properties. However, it is more difﬁcult to show
that a substance is not potentially hazardous. In order to address
this issue, the more recent literature has identiﬁed some of the
challenges which need to be taken into account when preparing
a read-across justiﬁcation (cf. Patlewicz et al., 2013a, 2014); specif-
ically, case studies have described the process to create a
read-across prediction increasing the likelihood of regulatory
acceptance (cf. Ball et al., 2014).
Much guidance on grouping of chemicals and read-across is
already available (ECETOC, 2012; ECHA, 2009, 2011; OECD, 2007,
2011, 2014a) and the key strategic documents have been sum-
marised in Table 1.4 of Cronin (2013a). This is a fast moving ﬁeld
and the formation of chemical categories, or the grouping of mole-
cules, especially to allow for the ﬁlling of data gaps by read-across,
588 T.W. Schultz et al. / Regulatory Toxicology and Pharmacology 72 (2015) 586–601has advanced markedly since the start of the 21st Century.
Background information on the processes of grouping and
read-across has been detailed by Cronin et al. (2013). It is clear that
interest in chemical category formation, coupled with read-across
for toxicological data gap ﬁlling, has grown for a number of reasons
(Cronin, 2013a). However, the primary drivers of this expansion
are legislation, which has forced the need for non-test methods
to assess chemical safety and the willingness of regulatory bodies,
although it is cautious, to accept read-across-based submissions in
lieu of test results. While there are various advantages and disad-
vantages to using the category-based read-across approach in tox-
icology (Patlewicz et al., 2013a,b; Cronin, 2013a), the advantages
appear to out-weight the disadvantages. As additional case studies
demonstrating the utility and practical application of read-across
become available, the advantages will become more prominent
and the challenges more readily addressed.
All applications of read-across are context dependent and any
read-across adaptation (i.e., the formal process by which a predic-
tion is used for regulatory purposes) is likely to be performed with
limited sets of experimental data. Thus, successful adaptations of a
read-across are contingent not only on the appropriate selection of
the characteristics, measures of similarity and assessment of the
uncertainties associated with the prediction, but also on the qual-
ity and quantity of the information and data used in the exercise.
Within the applicability domain of a chemical category,
read-across can be performed to ﬁll data gaps with a number of
approaches which can be summarised into the following four
techniques:
(1) one-to-one read-across (i.e., one source substance used to
make a prediction for a single target chemical),
(2) many-to-one read-across (i.e., two or more source sub-
stances used to make a prediction for a single target
chemical),
(3) one-to-many read-across (i.e., one source substance used to
make a prediction for two or more target chemicals), or
(4) many-to-many read-across (i.e., two or more source sub-
stances used to make predictions for two or more target
chemicals).
Techniques 3 and 4 may be considered as being multiple simul-
taneous applications of techniques 1 and 2, respectively. Given
limited data availability, the ‘‘one-to-one’’, or analogue approach,
is often the only viable option. Ideally, however, the
‘‘many-to-one’’ or category approach is preferred as it inherently
possesses a greater WoE in that each analogue in the category sup-
ports the others.
With reference to the above applications (one/many-to-
one/many), it is recognised that read-across for toxicity prediction
can be qualitative or quantitative in design. A qualitative
read-across provides a ‘‘yes/no’’ prediction for an effect; quantita-
tive read-across provides quantitative (i.e., potency) values for an
endpoint. When conducting a quantitative read-across exercise,
the OECD suggests that there are four main approaches to making
the prediction (OECD, 2014a):
(1) reading across from the endpoint value of a similar chemical
(e.g., the closest source chemical);
(2) applying a mathematical scale to the trend in available
experimental results from two or more chemicals similar
to the target chemical (e.g., trend analysis or structure–
activity relationships);
(3) processing the endpoint values from two or more source
chemicals (e.g., by averaging, by taking the most representa-
tive value), or;(4) when sufﬁcient data allow, taking the most conservative
value among the source chemicals within the whole
category.
Establishing similarity on an apical endpoint-speciﬁc basis is
essential to successful category formation and read-across
(ECETOC, 2012). Chemical similarity can be considered in a number
of ways (Enoch and Roberts, 2013). Critical to the justiﬁcation of
analogue(s) selection for read-across is the explanation of seminal
criteria of chemical similarity on which the selection is based. The
deﬁnition of these criteria is an on-going issue since chemical sim-
ilarity may be assessed in many ways and, even when assessed
objectively, not all measures of chemical similarity are of equal
importance and there is no simple similarity scale. In the extreme,
each chemical can be considered as its own category; however this
is obviously not practical for predictive purposes. In addition, it is
accepted that simple measures of chemical similarity (e.g., being
a member of a simple organic chemical class, having the same car-
bon skeleton or same function group) are often not practical for
making predictions. Thus, as noted by Enoch and Roberts (2013),
in order for any read-across prediction to gain acceptance, it is
essential to explain the basis for similarity between the target
chemical(s) and source chemical(s) in a robust and reliable manner.
After a read-across exercise is carried out, an assessment is
undertaken of whether the case supporting the read-across is suf-
ﬁcient for the prediction to be acceptable. This acceptance is often
stated in the form of conﬁdence or certainty. While the acceptance
of read-across predictions is often made according to a standard
procedure (e.g., an assessment framework), ultimately the evalua-
tor(s) must be convinced of the scientiﬁc credibility of the premise
of the read-across and the supporting data provided. Therefore,
assuming the rationale for similarity is accepted (i.e., the category
is robust and membership is assured), ﬁnal acceptance of the read
across prediction is contingent on reducing uncertainty. While
uncertainty is related to the quality and quantity of the read across
endpoint data (Cronin, 2013b; Péry et al., 2013; Blackburn and
Stuard, 2014), there are a number of other factors that inﬂuence
uncertainty.
2.1. Regulatory context and international efforts to address read-
across predictions
In order to understand the context of the development of
read-across, it is important to consider how it has been developed
and shaped as a data gap ﬁlling approach with regard to legislative
and regulatory pressure. Globally, a multiplicity of regulatory
agencies is applying read-across in their decision making pro-
cesses. While a number of these agencies are currently focusing
efforts on how to best standardise the development and evaluation
of read-across predictions, the European CHemical Agency (ECHA),
especially through the provisions in Registration, Evaluation,
Authorisation and Restriction of Chemicals (REACH) is among the
better known. Speciﬁcally, REACH allows for adaptations to the
standard information requirements by means of read-across of a
study conducted on a source substance to a target substance (cf.
Annex XI in EC, 2006).
The standard ECHA advice to registrants on making and docu-
menting a good-quality read-across/category (ECHA, 2013a,b)
refers to the importance of making a clear read-across hypothesis
and justiﬁcation. Non-testing approaches to data gap ﬁlling have
also garnered much attention at the Organisation for Economic
Co-operation and Development (OECD) and among its member
countries. Speciﬁcally, among the OECD member countries,
read-across is used as an alternative method for hazard identiﬁca-
tion and characterisation in risk assessments; read-across is
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every chemical needs to be tested (OECD, 2014c).
Since the regulatory use of read-across relies on the scientiﬁc
validity and the robustness of the justiﬁcation substantiating the
prediction for a given endpoint(s), there are a number of issues
associated with read-across which may beneﬁt from international
discussion on a broader scale. Experiences reported by the OECD
members indicate that there is still a lack of agreement on what
‘‘chemical similarity’’ is. Speciﬁcally, the OECD has noted the chal-
lenge posed by the facts that: (1) a chemical category is deﬁned by
a variety of factors, (2) there are no simple similarity scale(s), and
(3) similarity can also depend on the endpoint under consideration
(OECD, 2014c).
Work at OECD has revealed that similarity hypothesis can be
based on a variety of aspects, and deﬁnitions, of, chemistry.
OECD has also concluded that these methods of assessing similar-
ity are not equal in obtaining a robust chemical category for toxi-
cological read-across. Read-across based on mechanistic
similarity (e.g., common chemical interaction with a receptor) is
generally considered a better similarity hypothesis than an infor-
matics based similarity metric. However, knowledge of the mode
or mechanism of action is not always available, especially for the
more complex endpoints such as repeated dose toxicity.
Moreover, information on transformation products and the rate
of formation of these products is likely to be the key factor in
accepting read-across predictions. Thus, information derived from
experimental studies, as well as toxicokinetic information and
ADME information, will contribute to justify the prediction.
The current view of OECD (OECD, 2014c) is that more experi-
ence is needed on how the conﬁdence in the prediction could be
enhanced by providing more mechanistic transparency, using
experimental data from structural analogues, using data that are
supplemented by toxicokinetic and ADME information, and using
data that are supplemented by relevant in vitro and in chemico end-
points (i.e., incorporation of more information to increase the
WoE). More speciﬁcally, the OECD has emphasised the following
as being crucial to the successful application of read-across: (1)
the process of how to document the justiﬁcation for a
read-across, (2) consideration of how to perform read-across for
more complex endpoints (e.g., repeated dose toxicity), (3) develop-
ment of approaches and agreement of use of quantitative
read-across for hazard characterisation, (4) methods to better take
mechanistic considerations into account in grouping chemicals,
and (5) approaches to derive WoE conclusions based on results
from alternative methods or supplementary information provided.
While the details may vary, it is obvious from all the regulatory
requirements and guidance that any general strategy to assess the
justiﬁcation for a read-across prediction must examine whether or
not the key principles of similarity are clearly documented and
whether the interpretation is supported by scientiﬁc justiﬁcation
based on argumentation, literature and data. Development of the
similarity rationale, whether for an analogue or a chemical cate-
gory, must be performed on a case-by-case basis. This
case-by-case basis is likely to be inﬂuenced by the availability of
suitable data to populate the category and be speciﬁc to the regu-
latory endpoint being evaluated (i.e., complex endpoints may
intrinsically require greater conﬁdence in the similarity argument
and data). Read-across arguments often adopt a multifaceted
approach that combines several similarities into a single rationale.
This approach, where similarity between the source and target
chemicals is demonstrated across multiple parameters, is designed
to reduce uncertainty associated with the read-across prediction.
Acceptance of a read-across prediction is often couched in the
evaluator’s sense of conﬁdence or, more accurately, certainty in
the prediction. In the end, high conﬁdence (i.e., low concern about
potential error in the prediction) is assigned to a read-across whenthere is strong proof the prediction is valid (i.e., low uncertainty).
This conﬁdence is often gained by identifying and addressing the
sources of uncertainty.
Finally, it is recognised that the OECD is currently conducting
further work on the hazard assessment of chemicals. Through the
Task Force on Hazard Assessment, the OECD is developing
Integrated Approaches to Testing and Assessment (IATA).
Included in this effort is the examination of grouping approaches
and the exchange of experiences among the member countries
on new hazard assessment methodologies. A goal of this work is
to achieve a harmonised approach to the implementation of
IATA, so as to ensure consistency in how information is used in reg-
ulatory decision-making and to foster mutual acceptance of assess-
ments (OECD, 2014c). This knowledge and experience will add to
the understanding of the process of category formation and use
of read-across.3. Deﬁning the criteria for category membership: establishing
similarity
To meet regulatory needs, the read-across hypothesis, or justiﬁ-
cation for the read-across within a deﬁned chemical category of
discrete organic substances, must include a clear deﬁnition of the
criteria (i.e., chemical similarity) for membership of the category
(i.e., a clear deﬁnition of the applicability domain). Within the
REACH regulation, read-across is founded on the principle of
‘‘structural similarity’’ combined with a scientiﬁc justiﬁcation.
Therefore, within the OECD guidance for read-across, the basis
for assessing similarity is typically elaborated with the possibility
of other considerations (e.g., bioavailability, toxicokinet-
ics/metabolism) to assess analogue similarity (OECD, 2014a).
Moreover, a useful tool that might be employed for demonstrating
commonality in toxic behaviour is through an adverse outcome
pathway concept; this implies assessing similarity ‘‘via molecular
initiating events’’, ‘‘key intermediate events’’ and ‘‘other relative
in vitro’’ information and data (OECD, 2013, 2014b). Clearly, the
basis for establishing the applicability domain of a category will
depend both on the endpoint and chemical and means of forming
a category e.g. a speciﬁcally vs. broadly deﬁned fragment. Thus, the
questions ‘‘Can a chemical category be formed?’’ and ‘‘Is the cate-
gory toxicologically relevant?’’ are often addressed concurrently.
Building on six case studies using the information within the
OECD QSAR Toolbox (Enoch et al., 2013) and the earlier work of
Blackburn et al. (2011) and Wu et al. (2010), it is clear that chem-
ical category membership can be deﬁned by many factors. Table 1
summarises the factors leading to category membership being ade-
quately deﬁned and supported into three elements.
While there can be a starting premise or over-arching rationale
for grouping organic substances based on molecular structure and
chemical properties, these similarities alone are generally not suf-
ﬁcient to justify a read-across prediction. Typically, further infor-
mation is required to justify the chemical grouping on the basis
of considerations such as bioavailability, reactivity, and metabo-
lism. Similarity in bioavailability is also crucial to conﬁrm where
possible. Read-across should be performed where similar bioavail-
ability can be demonstrated. Currently, without experimental data,
it is difﬁcult to obtain realistic estimates of bioavailability in silico,
however progress is being made in areas such as predicting meta-
bolism and clearance rates which combined could provide usable
descriptors. For read-across predictions for the less complex end-
points (e.g., acute aquatic toxicity), adding these toxicokinetic sim-
ilarities is often enough to justify a read-across prediction.
However, for the more complex endpoints (e.g., chronic health tox-
icities), additional measures of similarity are necessary for
read-across prediction to be acceptable.
Table 1
Criteria for category membership.
(1) A description of structural and chemical property similarities and differences among the category analogues and how these similarities and differences are
linked to the read-across hypothesis
a. Supported by a data matrix of key structural and chemical properties
(2) A description of toxicokinetics and/or abiotic transformation similarities and differences among the category analogues and how these are linked to the read-
across hypothesis
a. Supported by a data matrix of abiotic and biotic modiﬁcation properties, including a summary of metabolic pathways and metabolites
(3) A description of the similarity and differences in the bioavailability of the chemical analogues and how these are linked to the read-across hypothesis
(4) A description of biological and toxicological similarities and differences among the category analogues and how these are linked to the read-across hypothesis
a. Supported by a data matrix of biological and toxicological properties including a summary of toxicological trends within the category
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eleven similarities which are proposed that to have an impact on
forming the chemical category for a read-across prediction, are
summarised in Table 2. In order to be both transparent and com-
prehensive, it is suggested to collect similarity data for as many cri-
teria as possible. Whilst molecular structure similarity is a highly
pragmatic approach to identify potential source analogues, it is
not on its own sufﬁcient to justify read across, and indeed it may
not be the most important element.
Data for molecular structure and physico-chemical properties
to support grouping hypotheses can be easily obtained in silico
from software such as the OECD QSAR Toolbox. Using
two-dimensional molecular structure, structural data can be
organised into groups of atoms representing rings (e.g., benzene
or naphthalene), linkers (i.e., atoms in a direct path connecting
two ring systems), frameworks (i.e., the combination of ring sys-
tems and linkers in a molecule), and side chains (i.e., non-ring,
non-linker atoms) (Bemis and Murcko, 1996). These molecular
scaffolds provide a basis for assessing similarity. Common con-
stituents include substituents (e.g., the 166 well-characterised,
common organic moieties described by Hansch and Leo (1979))
and structural fragments (e.g., the 645 fragments used in the US
EPA’s the Analog Identiﬁcation Methodology (AIM)). In addition,
physico-chemical and molecular property similarities include
properties which are linked to key factors that affect toxicity
(e.g., volatility, solubility, reactivity, etc.) (http://www.epa.gov/
oppt/sf/tools/aim.htm).
Five types of similarity (Items 3–7 in Table 2) are typically con-
sidered to meet the similarity hypotheses for grouping chemicals
for read-across based on common toxicokinetics and/or abiotic
transformation; these factors largely focus on metabolism which
often has signiﬁcant uncertainty associated with it due to the
potential difﬁculty in obtaining experimental or in silico data.
Transformation similarities focus on the likelihood of attaining
common or similar precursors and/or breakdown products, via
physical or biological processes. This includes key abiotic transfor-
mations (e.g., hydrolysis, autooxidation) and toxicokineticsTable 2
Similarities for establishing a toxicological read-across.
(1) Molecular structure similarity including common chemical class and sub-class
constituents in the form of key substituent(s), structural fragment(s) and ext
(2) Similar physico-chemical and molecular properties, especially those that are
reactivity, etc.)
(3) Similar toxicokinetics
(4) The same key abiotic transformation process (e.g., hydrolysis, autooxidation)
(5) The same key metabolic pathway(s) or pathway inhibition
(6) Biotic and abiotic activation to the same or similar reactive chemical species
(7) Abiotic (e.g. microbial) degradation to the same or similar chemical species
(8) Similar structural alert, or toxicophore, (i.e., structural fragment(s) and exte
speciﬁc toxic effect that is causally linked with the in vivo endpoint which is
(9) Mechanistic plausibility, especially in the form of a common Adverse Outcom
event(s) causally linked to the in vivo endpoint which is the basis of the read
(10) Other data (e.g., in vitro, in chemico, in silico) relevant to the in vivo endpoint
(11) Similarity in in vivo toxicological responses within the category(ADME), the same key metabolic pathway(s) or pathway inhibi-
tion, activation to same or similar reactive chemical species and
degradation to the same or similar chemical species.
For read-across based on common biological/toxicological fac-
tors, three types of similarity; toxicophores, mechanistic plausibil-
ity and related endpoints, are mostly considered (Table 2), the
most important of which is mechanistic plausibility. The AOP con-
struct, an excellent concept for adding mechanistic understanding
into the read-across, is one of several means of establishing mech-
anistic plausibility. In addition, similarity in the biological (prefer-
ably in vivo) data, such that are available will provided additional
evidence for category membership,
In the initial phase of developing a read-across, it is advisable to
collect information on similarity and data for as many of the crite-
ria listed in Table 2 as possible. However, it is intuitive that the
most critical measurements of similarity are endpoint- and
scenario-dependent and hence will require expert judgment and
application. In amassing information on similarity (for regulatory
applications in particular) it is essential to explain the basis for
the similarity between the target chemical(s) and the source chem-
ical(s) in sufﬁcient detail to be able to judge ﬁt for purpose. There
are a number of potential regulatory purposes for performing, and
uses of, a read-across prediction. The regulatory purposes include:
(1) prioritisation and screening, (2) hazard identiﬁcation (poten-
tial), (3) hazard characterisation (potency), and (4) safety assess-
ment (potential/potency and exposure). Thus, in assessing the
similarity associated with grouping, it is important to do so in
the context of the decision being considered and the scope of the
problem. The ‘‘context’’ and ‘‘scope’’ signiﬁcantly inﬂuence a num-
ber of issues including the similarity rationale(s) required to form
the category and identify analogues.
The regulatory purpose of the read-across often determines the
type(s) of similarity required. It is currently accepted (c.f., Cronin
et al. (2013)), that there are three broad criteria of similarity: (1)
chemistry, (2) transformation, and (3) toxicology. In consideration
of prioritisation and screening, hazard identiﬁcation and safety
assessments greater and more detailed information is required(es), similar molecular scaffold(s), similar numbers of carbon atoms and common
ended structural group(s)
linked to key factors that affect bioavailability toxicity (e.g., volatility, solubility,
nded structural group(s) experimentally demonstrated to be associated with a
read across)
e Pathway (AOP) based Molecular Initiating Event (MIE) and/or key intermediate
-across
which are the basis of the read-across
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to achieve the goal of ‘‘ﬁtness for purpose’’ (i.e., to be both trans-
parent and comprehensive in the justiﬁcation of a read-across) it
is advisable to collect data for as many of these similarity criteria
listed in Table 3 as possible. To assist in this process of collecting
and assessing information relating to similarity, a template for
assessing similarity of analogues and category members for
read-across has been proposed and is reported in Appendix A.
This proposed template to collect information to establish sim-
ilarity includes an overall conclusion regarding the rationale for
analogue/category similarity (this is provided as a text box in the
Template in Appendix A). The conclusion is intended to summarise
all relevant scientiﬁc information relating to establishing similar-
ity, in order to clearly justify the analogue(s) selected. The overall
rationale for similarity is established by assessing the various crite-
ria for similarity. This is achieved by answering the following ques-
tions relating to chemical, transformational and toxicological
similarity.4. Conﬁdence and uncertainty
There is general agreement that increased uncertainty has a
strong negative impact on a read-across prediction and often
negates the use of the read-across method. For that reason, uncer-
tainties need to be identiﬁed and appraised (Cronin et al., 2013;
Ball et al., 2014; Blackburn and Stuard, 2014; Patlewicz et al.,
2014). However, the concept and deﬁnition of uncertainty has been
described as ambiguous; it tends to incorporate a variety of
methodologies with the aim of meeting different goals (Péry
et al., 2013). As a result, a major challenge for the better use of
the read-across approach lies in making the concept of uncertainty
more understandable and transparent. Currently, determining how
much uncertainty is acceptable for a read-across prediction is still
largely subjective. It is deﬁned on a case-by-case basis and inﬂu-
enced heavily by the purpose of the prediction, the endpoint
assessed, and whether the read-across predicts the presence or
absence of toxicity.
To date, the most comprehensive method for gauging uncer-
tainty for read-across, especially for chronic health effects (e.g.,
repeated dose toxicity), is in the ‘‘framework’’ of Blackburn and
Stuard (2014). This is a prescriptive scheme for addressing the var-
ious facets of uncertainty as it pertains to read-across. Speciﬁcally,
it is designed to: (1) increase transparency of the read-across pre-
diction, (2) provide consistency to the exercise, (3) provide a
means of examining robustness and consistency among the key
facets of similarity, (4) facilitate review and evaluation of the
read-across exercise, and (5) help identify where additional data
may be helpful, especially in reducing uncertainty. The
Blackburn–Stuard framework does not, however, completelyTable 3
Criteria to establish similarities for a toxicological read-across.
 What are the chemical identiﬁers and structure of the target substance(s) and th
 Deﬁne the similarity in the physico-chemical and molecular properties of the tar
 Deﬁne the similarity of the key substituents, functional group(s) or extended fra
stance(s) and source analogue(s) have? (see Appendix A, Table A.3)
 Identify any structural differences between the target substance and source analo
 Establish how structural differences may affect toxicity (or otherwise) through si
 Deﬁne the similarity in abiotic transformations and/or toxicokinetics between th
 Deﬁne the similarity in potential metabolic products between the target substan
 Deﬁne the similarity in toxicophores or structural alerts for causally-linked toxi
Appendix A, Table A.6)
 Identify whether the target substance(s) and source analogue(s) have the same me
KEs (see Appendix A, Table A.7)
 Identify if the target substance(s) and source analogue(s) are linked by other toxremove subjectivity from the process, as expert judgment is still
required to categorise uncertainty. In addition, the Blackburn–
Stuard framework deﬁnes four levels of uncertainty (i.e., low, low
to medium, medium and high) and proposes quantitative factors
(i.e., 1, 3 and 10, respectively) for addressing the three lesser levels,
with the uppermost level of uncertainty being deemed unsuitable
for the application of the read-across method. The numerical
uncertainty factors serve to build conservatism into the potency
prediction and weigh the unknown associated with the prediction.
While the framework is new and largely untested, the scheme
appears to be good for repeated dose toxicity endpoints where
assessment factors can be applied to NOAELs. More quantitative
approaches for assessing uncertainty are provided below.
Sources of uncertainty include a variety of elements which are
typically divided into two main issues. The ﬁrst issue is uncertainty
associated with similarity justiﬁcation, and the second is associ-
ated with the overall approach and conclusion. With regard to
the uncertainty associated with similarity justiﬁcation, this implies
that there are inherent uncertainties associated with the presump-
tion that the results of the in vivo study/ies on the source chemi-
cal(s) apply (i.e., can be read across) to the target analogue(s).
The justiﬁcation for this presumption is based on two interrelated
rationales: (1) that the target and source materials are sufﬁciently
similar to be toxicologically relevant, and (2) that supporting argu-
ments are provided to justify that the differences in chemical
structure do not affect the properties relevant to the speciﬁc end-
point under consideration.
The assessment of uncertainty associated with similarity justi-
ﬁcation includes consideration of the information supporting the
scientiﬁc arguments for similarity and data associated with the
chemical, toxicokinetic and toxicodynamic similarity resulting in
the toxicity being read across. As stated previously,
chemical-based toxicological similarity may be established by
responding to the questions posed in Table 3 which may be
achieved by following the template presented in Appendix A.
Uncertainty associated with the answers to the questions in
Table 3 is assessed in a uniformmanner and a WoE, indicating con-
sistency in quality and quantiﬁcation of the data for each feature,
assigned (Appendix B, Table B.1).
Among the uncertainties are those brought about by deﬁcien-
cies in the underlying knowledge and data associated with assess-
ing the essential areas of similarity. Chemical similarity, in itself,
may never be enough to justify fully a read-across prediction.
While molecular structure and physico-chemical properties play
a role in assessing similarity, depending on the toxicological end-
point under consideration, these factors by themselves may not
be enough. For example, for chronic health endpoints, two struc-
turally similar chemicals may have signiﬁcant differences in toxic-
ity. In these cases, toxicokinetic and/or biological similarity may be
more important. When such information is lacking, speciﬁc studiese source analogue(s)? (see Appendix A, Table A.1)
get substance(s) and the source analogue(s). (see Appendix A, Table A.2)
gment, generic class of chemicals and sub-class of the target of the target sub-
gue(s)
milarities, for instance, in in vivo data
e target substance and source analogue(s) (see Appendix A, Table A.4)
ce and source analogue(s) (see Appendix A, Table A.5)
cological endpoints between the target substance and source analogue(s) (see
chanistical plausibility and can be linked mechanistically to the same AOP, MIE or
icologically relevant data (see Appendix A, Table A.8)
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tion or, as a minimum, reduce the uncertainty in the similarity to
an acceptable level for the intended purpose. Such a conﬁrmation
of biological similarity may be obtained from the comparison of
toxicological proﬁles derived from, for instance, non-animal tests.
However, in such cases, it may be complex and require expert
judgement to select the appropriate in chemico method, in vitro
assay or possibly an in silico tool to provide the critical information
needed to strengthen a similarity rationale.
The second issue of uncertainty is associated with the com-
pleteness of the read-across argument. The molecular nature
(e.g., complexity of molecular structure) of the target chemical(s),
the nature and complexity of the apical endpoint to be read across,
the premise or hypothesis of the read-across, the purpose of the
prediction as well as the quality and robustness of the data all
can have an impact on uncertainty, its deﬁnition and acceptability
for read-across (Table 5).
The molecular nature (e.g., complexity of structure) of the tar-
get chemical(s) (2nd bullet in Table 5) implies that target chemi-
cals with simple molecular structures (e.g., a hydrocarbon
scaffold and one functional group) impart less uncertainty than a
more complex molecular structure (e.g., a heteroatom scaffold
with multiple structural groups).
In terms of chemistry, the more narrowly deﬁned the applica-
bility domain of the grouping, the greater the conﬁdence can be
placed in the group membership and hence, the less the uncer-
tainty. For example, low uncertainty is associated with all category
members having the same functional groups and appropriately
similar key physico-chemical and molecular properties (e.g., ali-
phatic aldehydes with C2 to C5).
Relating to the problem and premise of read-across (1st bullet
in Table 5), it is intuitive that reading across from many-to-one
provides lower uncertainty than reading across from one-to-one,
assuming that the standard of the available in vivo data of the
source substances, and the trends within them, are comparable.
Further uncertainty may be associated with the apical endpoint
itself, which is to be read across. For some endpoints, chemical
mechanism and/or biological modes-of-action are well-
established (e.g., mutagenicity). However, for other endpoints
(e.g., repeated dose toxicity), the lack of a mechanistic understand-
ing tends to introduce greater uncertainty into the similarity ratio-
nale. Mechanistic uncertainty is best assessed within the context of
an AOP. It is recognised that knowledge of an AOP evolves and, as
such, AOP development represents a continuum from less-to-more
complete with increasing quality, quantiﬁcation and strength of
key events (KEs) and key event relationships (KERs) (Tollefsen
et al., 2014). Conﬁdence in using an AOP is typically informed
by: (1) support for the biological plausibility of KEs, KERs in rela-
tionship to the in vivo apical outcome under consideration, (2) sup-
port for the essentiality of the MIE and other KEs, and (3) empirical
data quantifying the KEs and support for the KERs.
As an example, typically, there is more uncertainty with a
developmental toxicity endpoint than a genotoxic endpoint. A
chemical which can cause DNA or chromosomal damage is deemed
a genotoxin. As such, many in vitro and in vivo tests for genotoxic-
ity have been developed with a range of endpoints that either
detect DNA or protein damage or a genotoxicity-related biological
consequence; causal linkage between the interaction of a chemical
with biomolecules at the molecular level and subsequent in vitro
and in vivo genotoxic effects are well-established (Petkov et al.,
2015). The net result is that there are practical methods of integrat-
ing in silico and in vitro results to reduce uncertainty in predicting
genotoxicity outcomes of untested chemicals. In contrast, there are
a variety of interactions of a chemical with biomolecules which can
subsequently lead to adverse developmental effects (Wu et al.,
2013). Many of the interactions that underpin developmentaltoxicity may not be deﬁned in detail and it may not be possible
to obtain data for Key Events in the AOP, even for well deﬁned
events. Thus, the read-across of developmental toxicity is implic-
itly associated with greater uncertainty than for well described
and ‘‘modelled’’ endpoints. Linked to this concept is the realisation
that there are several sources of uncertainty in supporting biolog-
ical justiﬁcation. These sources, which are relevant for all systemic
endpoints, include: (1) incomplete knowledge of the biological
mechanism(s) resulting in toxicity, (2) relevance and completeness
of the supporting evidence in the form of scientiﬁc information
and/or test data, and (3) problems with the test data (e.g., variabil-
ity in results, lack of understanding what the results mean, etc.).
Once the weaknesses or data insufﬁciencies in the justiﬁcation
are documented, new method evidence can be added to address
the shortcomings and reduce the uncertainty.
The read across endpoint(s) is another focal point of the exer-
cise. The type of read-across endpoint affects uncertainty and as
more complex endpoints are addressed, there will be a greater
WoE required to justify category membership. Simpler endpoints
(e.g., acute toxicity) may be readily addressed with fewer lines of
evidence supporting the biological justiﬁcation; often, a single tox-
icity proﬁler or small group of in vitro tests are sufﬁcient to estab-
lish the chemical category or analogue and support the
read-across. In contrast, for more complex endpoints, such as
chronic health effects which are traditionally assessed by higher
level in vivo tests (e.g., 28-day repeated dose testing), establishing
the category is more difﬁcult. In the case of complex endpoints,
analogues are often identiﬁed by WoE, looking at consistency in
empirical and/or model data across a number of mechanistically
relevant endpoints. For example, read across for skin sensitisation
may require a WoE call after gauging uncertainty in skin metabo-
lism or abiotic oxidation, as well as chemical reactivity leading to
protein binding and dendritic cell activation. In contrast, reading
across for oral in vivo mutagenicity may require gauging uncer-
tainty in microbial transformation in the gut, metabolic activation
in the liver and chemical reactivity leading to DNA-binding and
would probably require a lower overall WoE than for chronic tox-
icity. The depth and breathe of the information and empirical data
for these different activities affect the overall level of uncertainty
allowed, while still accepting the prediction via the WoE.
The problem and premise of the read-across signiﬁcantly inﬂu-
ence both the similarity rationale required to form an appropriate
chemical category and the empirical data of sufﬁcient quality
required for the source chemical. Thus, taking the scenarios sum-
marised in Table 4, in Scenario 1 toxicokinetics are less critical to
establishing similarity and establishing a source chemical as being
of high quality than in Scenario 2. In fact, the absence of toxicoki-
netic data for Scenario 2 may mean the uncertainty is too great as
to prevent the use of read-across without further testing. In addi-
tion, a read-across prediction of the absence of an adverse effect
carries with it a greater perception of uncertainty. In this case it
is not possible to demonstrate with absolute certainty that a target
chemical does not elicit a particular in vivo adverse effect (Scenario
3), however it may be possible to reduce uncertainty by demon-
strating the absence of sub-cellular and cellular responses (i.e.,
negative results from molecular screening and toxicogenomics).
In Scenario 4, one of the key questions to be addressed is whether
sub-categorisation is required to reduce the uncertainty associated
with the applicability domain of the read-across. The purpose of
the prediction also impacts the degree of uncertainty that is
acceptable.
While most previous publications discussing read-across have
focused on its application in safety assessment, read-across may
be used to ﬁll other needs. As noted earlier, there are four regula-
tory uses for using read-across predictions that apply three basic
types of similarity. The purpose of the prediction may determine
Table 4
Summary of the main types of read-across scenario.a
1. Chemical similarity of compounds that do not require (or do not undergo) metabolism to exert a potential adverse human health effect (i.e., direct-acting toxicants
with a similar mode of toxic action)
2. Chemical similarity involving metabolism and resulting in exposure to the same/similar toxicant (i.e., indirect-acting toxicants with a similar mode of toxic action
based on metabolites with the same mechanism of action)
3. Chemical similarity of compounds with low general or no toxicity (i.e., toxicants with no obvious reactive or speciﬁc mode of action)
4. Distinguishing chemicals in a structurally similar category with variable toxicities based on Mode of Action hypothesis (i.e., toxicants with high structural similarity
but markedly different potency and/or phenotypic proﬁles)
a From Schultz (2014).
Table 5
Proposed factors affecting uncertainty associated with the mechanistic relevance and completeness of the read-across.
(1) The problem and premise of the read-across. What is the level of complexity of the read across endpoint? What is the purpose of the exercise? What is the over-
arching premise and scenario of the exercise?
(2) Number of source chemicals and their relative applicability domain(s); is it an analogue-or category-based read-across?
(3) Absence/presence of toxicity and relevant mechanisms e.g. whether mechanisms can be deﬁned for non/low toxicity compounds
(4) Quality of the in vivo apical endpoint data read across to include technical issues related to the performance (e.g., reliability accuracy, precision, repeatability and
reproducibility of the manner in which apical in vivo data are generated). Is the data to be read across sufﬁcient to meet the purpose of the exercise?
(5) Consistency in the severity of the apical in vivo hazard. Is the potency of the hazard consistent among the source chemicals?
(6) Robustness of the (in chemico, in vitro and/or other) data sets. How extensive are the relevant events empirically measured or modelled? What is the performance
(e.g. in terms of reliability and reproducibility) of methodology for establishing these data?
(7) Concordance of the in chemico, in vitro and/or other data with regard to the intermediate and apical effects and potency data. What is the temporal and dose–
response relationship between mechanistically-relevant endpoints?
(8) The overall Weight-of-Evidence (WoE) supporting the prediction. How many and how large are the mechanistically-related data gaps?
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ences uncertainty. Prioritisation and screening may be amenable
to prediction based only on information from analogue chemistry.
Hazard identiﬁcation may require information on both chemistry
and toxicology similarity. However, hazard quantiﬁcation for risk
assessment will normally needs dosing route and transformation
similarity to assess exposure and toxicological similarity; in addi-
tion there may be an assessment of mechanistic plausibility, per-
haps based on an AOP.
The uncertainty that is associated with the in vivo toxicology
study/ies on the source chemical(s) is always case-speciﬁc.
Assessments should focus on any deﬁciencies in the quality of
the toxicology data to be read across, especially as compared to
what is expected from current standard test methods. Questions
3–4 in Table 5 are designed to address uncertainty associated with
the in vivo data being read across (a number of methods are avail-
able to ascertain toxicity data quality, with the reader being
referred to (Klimisch et al., 1997; Przybylak et al., 2012;
Steinmetz et al., 2014; Yang et al., 2013) for further information).
Conversely, the ﬁnal three questions in Table 5 are designed to
address uncertainty associated with in chemico, in vitro or in silico
data used to strengthen the similarity rationale. Lower uncertainty
may also be assigned when empirical and in silicomeasurements of
chemical properties are in good agreement.
The qualiﬁcation of transformation impacts uncertainty, espe-
cially with respect to metabolism for the category members with-
out empirical data. For example, low uncertainty is associated
when all category members have similar ADME properties.
Although there is uncertainty associated with predictions from in
silico tools, the uncertainty is considered lower when empirical
studies (in vivo and/or in vitro) and model predictions indicate sim-
ilar metabolism. In addition, information on the purity of com-
pounds being considered and read across must be included as
this may affect the certainty.
The uncertainty associated with a read-across prediction is
impacted by several additional features, especially those associ-
ated with the completeness and application of the read-across pro-
cedure; this knowledge is typically summarised in an overall
assessment of the WoE. In assessing the uncertainties associatedwith a particular read-across, it is important to put in context both
the problem and premise of the read-across. A statement of the
problem includes noting the target chemical(s), the apical endpoint
to be read across and the purpose of the prediction. Stating the tar-
get chemical(s) is critical, as it is one of the focal points of the
exercise.
Scaling uncertainty is a formidable challenge (Péry et al., 2013;
Blackburn and Stuard, 2014). While there is much agreement on
what the essential issues of the read-across are that need to be
considered in assessing uncertainty, there is less agreement on
what approach to use. At least three approaches could be applied:
(1) a sliding scale, which can be tailored to the particulars of the
read-across (i.e., problem and premise), (2) a weighted scale,
where some issues or their related narrative and/or question(s)
used to frame the issue are weighed more than others, and (3)
pre-deﬁned divisions, where all issues or their related narrative
and/or questions are assigned a value in a parallel fashion. The ﬁrst
two approaches, while interesting academic exercises are likely to
be too complex to be practical. Thus, the third approach, the
pre-deﬁned divisions approach, is the most likely to be used.
Within the latter approach, there is variability in the number of
divisions employed. A dichotomous decision scheme (i.e., accept
or reject) does not provide any reﬁnement to the assessment;
whereas, a multi-divisional scheme will provide the opportunity
to add conﬁdence statements into the assessment (e.g., low. med-
ium, high). A ﬁve-division scheme (or larger) may offer too much
subjectivity in assigning the division. The four-division scheme
(i.e., low, low to moderate, moderate and high) described by
Blackburn and Stuard (2014), appears to provide a balance
between a high number of possible divisions and reduced subjec-
tivity in assigning the ﬁnal division. The Blackburn and Stuard
scheme provides three divisions of uncertainty where the predic-
tion may potentially be usable; with the fourth division indicating
high uncertainty such that the read-across method is unﬁt for data
gap ﬁlling. The ‘‘characteristics by uncertainty’’ for the low and
low-to-medium divisions are much the same, with latter divisions
including a WoE evaluation. Initially, read-across case studies are
likely to involve extremely-well studied categories and analogues
which ﬁt the low uncertainty division of Blackburn and Stuard
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dictions, especially for chronic health effects, should include a WoE
evaluation.
Uncertainty factors are used to build conservatism into assess-
ments and address the unknown associated with a prediction.
Converting uncertainty ‘‘divisions’’ (as reported by Blackburn and
Stuard, 2014) to numerical uncertainty factors provides another
challenge. Excluding the ‘‘high’’ uncertainty division, since reach-
ing this level of uncertainty precludes using read-across to ﬁll a
data gap, one is left with assigning three uncertainty factors.
There are a variety of numerical scales (e.g., 1-2-3; 1-10-100;
1-3-10; 1-5-10) which may be employed to cover a
three-division scheme. A 1-2-3 method provides insufﬁcient differ-
entiation of uncertainty; conversely, a 1-10-100 provides too much
differentiation. The 1-3-10 method proposed by Blackburn and
Stuard (2014) remains a pragmatic and usable solution and is rec-
ommended for use at this time. However, as case studies become
available, especially for those where the read-across is less conclu-
sive (i.e., low-moderate or moderate), further evidence may
become available to evaluate this proposal more fully, for example
to explore the difference in employing a 1-3-10 versus a 1-5-10
quantiﬁcation method.
Table 6 summarises the main similarities that need to be con-
sidered when assessing a read-across justiﬁcation, along with
how they may be related to speciﬁc levels of uncertainty. Table 6
also demonstrates the value of including novel toxicological data
to read-across predictions with the aim of decreasing uncertainty.
It is likely that uncertainty associated with core structure and func-
tional groups, as well as physicochemical and molecular proper-
ties, can be assessed relatively easily. However, because of
information gaps, it is likely that uncertainty associated with com-
parable toxicokinetics and similar mechanistic and toxicological
properties, especially for chronic health endpoints, will be more
difﬁcult to assess.
Consideration of all the evidence (e.g., the uncertainties deﬁned
in queries such as Table 5, supporting data and information etc.)
provides the basis for the WoE. It is not only the quantity and qual-
ity of evidence that affects WoE but also consistency across all
aspects of the information/data used to support the similarity
rational and prediction. For example, whilst relative uncertainties
may be the same, it is intuitive that reading across from
many-to-one with consistent phenotypic expressions of toxicity
provides a greater WoE than reading across from many-to-one
with varied phenotypic expressions of toxicity. This has particular
implications in Scenario 4 of Table 4 where multiple mechanisms
of action may be present. In terms of chemistry, a greater WoE isTable 6
Proposed key similarities relating to toxicological read-across and criteria for assessing un
Low uncertainty Low-to-
Core structural similarity i.e.,
functional groups, extended
fragments (especially those
associated with chemical
reactivity or its modiﬁcation)
Highly similar Highly s
Physico-chemical and molecular
properties
Highly similar Similar,
with
Abiotic transformation and/or
toxicokinetics, especially
metabolism e.g., leading to a
common metabolite
Evidence demonstrating
comparability in abiotic
transformation and/or
toxicokinetics and the same
metabolites, similar
bioavailability
Evidenc
comp
trans
toxic
meta
bioav
Mechanism of action and
toxicological properties
Evidence demonstrating
comparability in mechanism
supported by an AOP
Evidenc
comp
possiassigned when empirical and in silico estimates of chemical prop-
erties are in good agreement with measured values. In a similar
fashion, the WoE is considered higher when empirical studies of
metabolism (in vivo and/or in vitro) and model predictions indicate
similar metabolites. Mechanistic plausibility can be more difﬁcult
to consider, however consistent empirical data for the target chem-
ical and, where possible, the target chemical and the source chem-
ical(s) for the MIE and/or other KEs strengthen the WoE. Similar
arguments can be made for other relevant, in vivo, in vitro and
ex vivo endpoints. Concordance across other endpoints (where data
exist) is also a relevant consideration. For example, acute oral LD50
data are not part of the mechanistic understanding for oral
repeated dose toxicity but having a consistent trend in empirical
data among category members may improve the overall WoE.
A template has been provided to identify and assess uncertainty
in a comprehensive and transparent manner. The template is avail-
able in Appendix B and it is recommended for use to assess the
uncertainty associated with each similarity parameter used in
the read-across and to summarise these ﬁnding in a statement of
uncertainty. The ﬁrst aim of the template was to identify the fac-
tors of the read-across that contribute to uncertainty in the predic-
tion. These include uncertainty associated with the scientiﬁc
justiﬁcation of the similarity that deﬁnes the applicability domain
of the category or source and target analogue, as well as the uncer-
tainty associated with the read-across. The second aim was to
deﬁne levels of uncertainty and propose quantitative factors for
addressing each level.
Table B.1 of the template in Appendix B lists and describes the
key issues of chemical, transformation/toxicokinetic and toxicolog-
ical similarity proposed to assess data uncertainty and WoE (see
Tables A.1–A.8). The comment column is not intended to be all
inclusive but rather give an indication of the type information that
may be included. Table B.2 of the template in Appendix B provides
the capability to assess the issues raised in Table 5 above. The aim
was to assess the non-similarity-based uncertainty associated with
the read-across. The ﬁrst item in Table 5 focuses on the particular
read-across problem being addressed. The second to fourth items
address the in vivo data relevant to the read-across. Items ﬁve
and six relate to the mechanistically-related in chemico, in vitro
and ‘‘new methods’’ data. Item seven addresses the overall WoE.
While a ranking (i.e., low medium or high) is assigned to each item,
the comment section is considered to bemore signiﬁcant and hence
of greater value. The overall ranking (low, moderate, high) and a
summary of the uncertainty associated with the deﬁnition of the
similarity of analogues or category members, as reported at the
end of the relevant tables, is presented in a text box in Appendix B.certainty (adapted from considerations in Blackburn and Stuard (2014)).
moderate uncertainty Moderate uncertainty High uncertainty
imilar Similar Differences in core
structure and
functional groups
having a consistent trend
in values
Minor differences in
values
Major differences in
values
e demonstrating
arability in abiotic
formation and/or
okinetics and the same
bolites, similar
ailability
No evidence that abiotic
transformation and/or
toxicokinetics,
especially metabolism
are dissimilar
Differences in abiotic
transformation
and/or
toxicokinetics,
especially in
metabolism
e demonstrating
arability in mechanism,
bly supported by an AOP
No evidence that
mechanisms of action
are dissimilar
Differences in
mechanism of
action and/or
toxicological
properties
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Existing workﬂows for reporting read-across predictions vary in
detail, however the general purpose is to: (1) describe the similar-
ity rationale of the read-across in a transparent manner, (2) docu-
ment the logic and data leading to the read-across prediction so it
can be recreated, (3) describe and address the uncertainties, and
(4) clarify the roles of any endpoint speciﬁc and/or endpoint
non-speciﬁc factors affecting the assessment.
In order to assist with developing a workﬂow for reporting, the
combined process of chemical category formation and toxicologi-
cal read-across prediction can be sub-divided into distinct and
deﬁnable activities. Cronin (2013a) identiﬁed six such procedures
associated with development of a read-across prediction including:
(1) the identiﬁcation of the effect and/or endpoint to be predicted
by read-across and the ‘‘target’’ chemical(s), (2) the identiﬁcation
the source chemical(s) and other chemicals ‘‘similar’’ to the target,
(3) obtaining toxicity data for the category members identiﬁed in 1
and 2, (4) deﬁnition of the chemical category, (5) making the pre-
diction of toxicity by read-across, and (6) fully documenting the
prediction.
More recently, the OECD has provided reporting formats for
analogue and chemical category approaches (OECD, 2014a). The
documentation of read-across predictions, which are largely based
on process of using the OECD QSAR Toolbox, includes a number of
steps:
(1) Formulate the problem (i.e., understand the assessment
strategy and identify the critical data needs).
(2) Curate chemical structure of the target compound(s) and
other category members.
(3) Proﬁle the target compound(s) and other category members.
(4) Develop the similarity rationale for the read-across
prediction.
(5) Establish the category selection criteria and search for
potential source analogues or category members.
(6) Gather data for the category members and construction of
data matrix.
(7) Assess the adequacy and uncertainty associated with the
read-across.
(8) Apply read-across to ﬁll the data gap.
(9) Document the analogue/category and read-across prediction.
A workﬂow proposed for reporting a read-across prediction is
presented in Appendix C. This builds on the earlier efforts and
reﬂects the essential points described in this paper to address sim-
ilarity, the data and to justify the validity of the prediction.
6. Discussion
A signiﬁcant proportion of REACH registration dossiers include
a read-across prediction intended to ﬁll information requirementsTable 7
The most likely scenarios for a chronic toxicity endpoint read-across.
(1) A ‘low-toxicity’ or negative read-across prediction; the category members ha
well-documented or easily predicted (from related chemicals) pathways tha
metabolites and there is no obvious chemical reactivity or bioactivity or
concentrations)
(2) A ‘toxicity’ or positive read-across prediction; the category members are dire
toxicity) with similar chemical mechanism-of-action and mode-of-toxic action
ing to an established structural-related trend) leading to the same read acros
(3) A ‘toxicity’ or positive read-across prediction; the category members are ind
deﬁnitive toxicants has the same chemical mechanism-of-action and elicits t
(4) A ‘toxicity’ or positive read-across prediction; the category members are struc
ity. Subsequently, new methods data reveal dissimilarity in bioactivity, often
appropriate read across endpoint effect (e.g., target organ and disease) requirfor higher-tier toxicological studies. In fact, 75% of registration dos-
siers include read-across or categorisation reasoning (ECHA, 2014)
by the registrant.
Improvements in methodology to perform and report
read-across prediction require an understanding of the process,
speciﬁcally around the concept of similarity with regard to two
or more chemicals. Berggren et al. (2015) noted that in considering
chemical similarities there are different aspects that must be
assessed to make the read-across prediction scientiﬁcally justiﬁed.
These similarities include aspects of chemical stability, the possible
formation of toxic metabolites, different active functional groups
that might lead to similar or dissimilar behaviours, possible routes
of exposure and concentrations at the target tissue, biotransforma-
tion (prior to reaching, or at, the target organ), or observable trends
with or without a mechanistic explanation. To improve and stan-
dardise the development and reporting of a read-across prediction,
it is, therefore, useful to identify different scenarios by which a
read-across prediction may develop. While this is possible to do
in several ways, the toxicokinetic fate of the substance, such as
whether the compound itself would be available in the target
organ or whether it would be its metabolites or reaction products
leading to adverse effect, is a critical factor, especially for chronic
health effects (Berggren et al., 2015). In addition, Berggren et al.
(2015) noted that the toxicodynamic behaviour of the substance
and compared similarities of chemicals based on their assumed
mechanism of action, including lack of biological activity, is critical
to establish a read-across justiﬁcation.
Category-based read-across adaptations begin with the deﬁni-
tion of a chemical category (i.e., establishment of the category’s
applicability domain). This deﬁnition is assumed to be related to
the toxicological property to be read across, which results from a
trend observed when the property to be read across is plotted
against another property that is known for all members of the cat-
egory (i.e., an indication of toxicological relevance). Read-across to
a target substance is deemed possible when the target substance is
an unambiguous member of the category and there are one or
more measured property(ies) to be read across for other
members of the category. Therefore, a category-approach
read-across is based on grouping and may rely on one or more
observed trends. Category-approach read-across also covers cases
where substances belonging to a well-deﬁned category all show
the same type and value for the toxicological property to be read
across or do not show an effect at all (i.e., a ‘low-toxicity’
read-across case).
While there is no consensus, there appear to be four most likely
scenarios where chemical category formation and subsequent
read-across may be used to ﬁll a data gap, especially for repeated
dose toxicity. Scenarios for read-across in general are described
in Table 4, more speciﬁc scenarios for chronic endpoints are given
in Table 7.
It is important to remember that deﬁning the criteria for cate-
gory membership for a particular scenario of chemical categoryve structural and chemical similarities, toxicokinetics are simple and based on
t lead to rapid degradation and/or elimination and/or generation of non-toxic
speciﬁc mode-of-action (i.e., members elicit generic effects but only at high
ct-acting toxicants (i.e., no transformation or transformation does not drive the
(i.e., members elicit speciﬁc effects at similar internal concentrations or accord-
s effect
irect-acting toxicants (i.e., transformation is the driver of toxicity), where the
he same mode-of-toxic action leading to the same read across effect
turally and chemically highly similar and initially considered similar in bioactiv-
due to the inhibition of a degradative metabolic pathway. Thus, to obtain the
es sub-categorisation
Table A.2
Comparison of physico-chemical and molecular properties.1
Table A.1
Comparison of substance identiﬁcation, structure and chemical classiﬁcations.
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Improvement in the conﬁdence of a read-across prediction can
be made by added value in the form of increased WoE. This added
value may come from suggestions of how targeted testing and
‘‘new-approach’’ data, especially when applied using the logic of
the Safety Evaluation Ultimately Replacing Animal Testing
(SEURAT) conceptual framework (White and Knight, 2013), may
be used to improve the read-across justiﬁcation. The increase in
justiﬁcation will be especially true if targeted testing focuses on
the weak steps of the read-across argument. In other words, an
understanding of how targeted testing may reduce uncertainty is
available, for instance as stated in Table 6. The improvement of
the robustness of the read-across predictions, when further evi-
dence is added can, in principle, be examined by various means
before and after the addition of further evidence.
The intention of this manuscript was to report progress in the
development of proposed templates and workﬂows for recording
and evaluating traditional in vivo toxicology data, as well as alter-
native methods (e.g., in chemico, in vitro) data. Additionally, the
intent was to suggest means to standardise the evaluation of sim-
ilarity and uncertainty so as to enhance the robustness of the
read-across prediction and thereby make it more likely to gain reg-
ulatory acceptance.
Since there are various over-arching scenarios for category for-
mation and read-across, it is critical to not only state the target
chemical and its missing endpoint value but also the hypothesis
and assumptions on which the read-across is based. A cate-
gory/analogue hypothesis typically makes references to several
similarity rationales which delineate category membership. For
example, for a read-across adaptation of Scenario 3 noted in
Table 7 it may be possibly to report:
 Members of chemical category A are indirect-acting toxicants of
n1 to n2 carbon atoms in size with a molecular scaffolding of B
and the primary functional group C.
 Category members elicit a similar chemical mechanism-of-
action (e.g., electrophilic reactivity via mechanism D), where
metabolism via pathway E is the primary factor driving the
reactivity leading to oral repeated dose toxicity with symp-
toms/endpoints F.
 Category members show rapid and complete absorption from
the gut, as the parent compound with ﬁrst past through oxida-
tive metabolism in the liver to the corresponding electrophile
with mechanism D. Subsequently, the electrophile elicits the
in vitro outcome G at the cellular level leading to the in vivo out-
come F.
 Category members have similar volatility, bioavailability and
oral uptake.
 Reading repeated dose toxic outcome F for the source chemical
X across to the target chemical Y is supported by information
and data on A, B, C, D, E and G.
Along the same theme, assessments of uncertainty may reveal
there are no deﬁciencies in the quality of the toxicology data to
be read across (F), especially as compared to what is expected from
current standard test methods. However, assessment of
uncertainty associated with similarity justiﬁcation reveals metabo-
lism via pathway E to be the weak step of the read-across argu-
ment. New methods data following targeted testing may reduce
the uncertainty by strengthening this step in the similarity
argument.Target Substance Analogue 1 Analogue n
Boiling Point
pKa
1 Value typically derived from EPISuite v4.0.Conﬂict of interest
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Cosmetics Association Cosmetics Europe.Appendix A. Template for reporting data for assessing similarity
of analogues and category members for read-across
In Table A.1, the substance identiﬁcation information, 2D struc-
ture and molecular formula data for the target substance(s) and
proposed source analogue(s) are presented for comparison. The
purpose of this information is to provide, in a transparent manner,
a preliminary basis for assessing similarity.
In Table A.2, selected physico-chemical and molecular property
data for the target substance(s) and proposed source analogue(s)
are presented for comparison. The purpose of this information is
to provide, in a transparent manner, the chemical property basis
for assessing similarity. These data may assist in deﬁning the
boundaries of the applicability domain of the category, especially
in regards to in vivo (bioavailability) and in vitro (solubility)
toxicity.
In Table A.3, substituents, functional groups and extended
structural fragments as well as chemical class data for the target
substance(s) and proposed source analogue(s) are presented for
comparison. The purpose of this information is to provide, in a
transparent manner, the chemical structure sub-fragments and
chemical class data for assessing similarity. These data may assist
Table A.7
Comparison of mechanistic plausibility and AOP-related event data.
Target Substance Analogue 1 Analogue 2
Name
Mechanistic Plausibility
Adverse Outcome Pathway or 
Mode of Toxic Action:
Molecular Initiating Event:
Key Event 1 etc.: 
Key Event Relationship 1 etc.:
Other Mechanistically-Relevant 
Events
Table A.3
Comparison of substituents, functional groups, and extended structural fragments.
Target Substance Analogue 1 Analogue 2
Name
Key Substituent(s)
Functional Group(s)
Extended Fragment(s)
Chemical Class:
Chemical Sub-Class:
Chemical Sub-Class:
Table A.4
Comparison of abiotic transformation and toxicokinetics.
Target Substance Analogue 1 Analogue 2
Name
Target Substance Analogue 1 Analogue 2
Abiotic Transformation
Toxicokinetics
Table A.6
Comparison toxicophores.
Target Substance Analogue 1 Analogue 2
Name
Target Substance Analogue 1 Analogue 2
Toxicophores
Table A.8
Comparison of other toxicologically relevant in vivo, in vitro and ex vivo data.
Target Substance Analogue 1 Analogue 2
Name
Endpoint:
Endpoint:
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category.
In Table A.4, transformation information and data for the target
substance(s) and proposed source analogue(s) are presented for
comparison. The purpose of this information is to provide, in a
transparent manner, assessing similarity in abiotic transformation
and/or similarity in the absorption, distribution, metabolism and
elimination information.
In Table A.5, the predictions of potential metabolites derived
from in silico tools data for the target substance(s) and proposed
source analogue(s) are presented for comparison. A number of soft-
ware platforms provide in silico predictions of metabolism. These
are typically based on simulations run on the parent compound
and initial metabolites using well-studied reactions, such as oxida-
tion. Files with name and structure of metabolites should be
included for the sake of transparency.
In Table A.6, any toxicophore (i.e., toxic endpoint-speciﬁc struc-
tural alerts) data for the target substance(s) and proposed source
analogue(s) are presented for comparison. A number of software
platforms provide in silico predictions based on the presence of
toxicophores (e.g., OECD QSAR Toolbox, Derek Nexus). The purpose
of this information is to provide, in a transparent manner, any
chemical structure sub-fragments linked to any relevant biological
endpoint for assessing similarity.
In Table A.7, any mechanistic plausibility data including
AOP-related, MIE, KEs, KERs or other mechanistically-relevant end-
points for the target substance(s) and proposed source analogue(s)
are presented for comparison. With few exceptions (e.g., skin sen-
sitisation), there are currently a limited number of endpoints for
which AOPs, MIEs and KEs test methods and data have beenTable A.5
Comparison of potential metabolic products.
Target Substance Analogue 1 Analogue 2
Name
Liver metabolism 
simulator e.g. OECD
QSAR Toolbox
Other software e.g. 
MetaPrint2D-React 
software
Further software for 
prediction of metabolitesformally developed and causally-linked, especially in the form of
a KER. However, in the future, these pieces of information will
become more and more available.
In Table A.8, any other toxicologically relevant data for the tar-
get substance(s) and proposed source analogue(s) are presented
for comparison. In some cases, there is relevant data from other
sources (e.g., alternative species) which can assist in establishing
mechanistic similarity.
Appendix B. Template for assessing uncertainty for read-across
See Appendix Tables B1 and B2.
Summary of uncertainty
Example: Overall, the uncertainty in similarity of the analogues
or category member is low. The key features (i.e., A and B) relevant
for toxicity are common within the category. There are only minor
differences among the analogues or category members with
respect to physicochemical properties. Analogues or category
members are considered chemically similar (i.e., C). Analogues or
category members are judged to follow the same or similar meta-
bolism. Analogues or category members exhibit a similar toxico-
logical proﬁle (i.e., D and E) with respect to the endpoint in
question. It is concluded that the structural difference between
analogues, hydrocarbon chain length, has no signiﬁcant impact
on the toxicity being read across.
Appendix C. Work ﬂow for reporting a read-across prediction
1. Statement target substance(s) and the regulatory endpoint(s) that is
to be read across
The speciﬁc data gap to be ﬁlled by the prediction needs to be
clearly deﬁned by listing the chemical(s) and toxicity endpoint(s)
(i.e., property(s)) for which the read-across prediction is proposed.
Table B.1
Data uncertainty and Weight-of-Evidence associated with the fundamentals of chemical, transformation/toxicokinetic and toxicological
similarity.
In vivo
In vivo
a Uncertainty associated with underlying information/data used in the exercise.
b Consistency within the information/data used to support the similarity rational and prediction.
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2.1. Premise
A premise for the basis of the analogue or category needs to be
presented. This hypothesis should note the relational chemical,
toxicokinetic and biological/toxicological features (i.e., structural
similarities) which are deemed to be collectively relevant to the
endpoint(s) being read across and common to target and source
substance or all members of the category.2.2. Justiﬁcation
The analogue or category should be justiﬁed based on available
experimental data, especially for the source substance(s). This is a
description of the experimental toxicological data for the ana-
logues or category members, presented in a narrative fashion.
Typically, this justiﬁcation will include endpoint-related mam-
malian toxicity data via appropriate exposure schemes, toxicoki-
netic and transformation information, as well as relevant in vitro
data and structure–activity relationships. These data should
Table B.2
Template for assessing uncertainty associated with mechanistic relevance and completeness of the read-across.
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across is sufﬁcient to proceed with the exercise. Moreover, these
data should be summarised to show the robustness of the
read-across and include any indication of data trend(s) within
the category for the different endpoints noted.
2.3. Applicability domain
In a category approach, the applicability domain of the category
is described by inclusion and/or exclusion rules that identify the
extent of values for category members within which reliable pre-
dictions can be made. Examples of this are the range of
1-octanol/water partition coefﬁcients values, functional groups or
carbon chain lengths within which the category is appropriate.2.4. Analogues or category members
Analogues or all members of the category, including target(s)
and source substance(s), incorporated in the read-across exercise
need to be described in a comprehensive fashion that takes into
account unique substance identiﬁers such as, names, chemical
structures and CAS numbers.2.5. Purity/impurities
A purity/impurity proﬁle for each analogue listed in 2.4 needs
to be catalogued. The potential impact of impurities on the
endpoint(s) being considered in the adaptation should be
identiﬁed.
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Appendix A presented the template for assessing similarity.
These data matrices are the central part of the workﬂow. They
are likely to be the ﬁrst items examined in any assessed. Data
should be reported clearly, logically and unambiguously. The key
study results should be noted and referenced. The distinction
between experimentally measured and model-derived data should
be noted.
4. Statement of uncertainty
Appendix B presented the template for assessing uncertainty.
This section concludes with a narrative summary of the uncer-
tainty. Particular consideration needs to be given to pointing out
what are considered to be the weak steps of the read-across argu-
ment; why they are considered weak and how they impact the
uncertainty of the read-across prediction.
5. Statement of the conclusions
Lastly, an overall concluding statement is made with regard to
the category and the read across prediction relevant to the regula-
tory decision (e.g., hazard identiﬁcation, classiﬁcation and label-
ling, risk assessment, etc.) being considered. This should include
making the prediction of toxicity by read-across and fully docu-
menting the prediction to include clarifying the roles of any end-
point speciﬁc and/or endpoint non-speciﬁc factors affecting the
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